New drug trial targets specific genetic driver in advanced lung cancer
NCT ID NCT05751018
Summary
This study is testing an oral drug called pyrotinib as the first treatment for people with advanced non-small cell lung cancer that has specific HER2 genetic changes. The goal is to see if the drug is safe and effective at shrinking tumors and controlling the cancer. Researchers will measure how many patients respond, how long the cancer stays controlled, and how treatment affects quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College
RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.